Skip to main content

Advertisement

Table 1 Baseline characteristics of patients

From: Pilot study using 3D–longitudinal strain computation in a multi-parametric approach for best selecting responders to cardiac resynchronization therapy

  All patients (n = 48) CRT responders (n = 34, 71%) CRT non-responders (n = 14, 29%) P value
Age (years) 65 ± 10 64 ± 10 65 ± 11 0.893
Male, n (%) 30 (63%) 18 (53%) 12(86%) 0.033*
Ischemic etiology, n (%) 15(31%) 8 (24%) 7 (50%) 0.094
Heart rate (bpm) 69 ± 12 68 ± 12 71 ± 11 0.489
QRS duration (ms) 160 [160; 170] 160 [160; 170] 160 [153; 170] 0.649
QRS & 150 ms, n (%) 40 (83%) 29 (85%) 11 (79%) 0.676
LBBB morphology, n (%) 38 (79%) 27 (79%) 11 (79%) 1
ACE inhibitors or AR blockers, n (%) 46 (96%) 33 (97%) 13(93%) 0.503
β-blockers, n (%) 46 (96%) 33 (97%) 13(93%) 0.503
Diuretics, n (%) 28 (58%) 16 (47%) 12(86%) 0.014*
Antialdosterone, n (%) 18(38%) 14(41%) 4 (29%) 0.412
LVEF (%) 26 ± 6 28 ± 5 23 ± 5 0.002*
LVEDV (ml) 225 ± 85 209 ± 78 265 ± 89 0.037*
LVESV (ml) 169 ± 68 152 ± 57 207 ± 78 0.009*
Mitral regurgitation grade lll-IV, n (%) 10(21%) 7(21%) 3(21%) 0.0767
TAPSE (mm) 21 + 4 21 ± 4 20 ± 5 0.78
GLS (%) − 8.9 ± 3.6 − 9.8 ± 3.4 − 6.5 ± 3.1 0.003*
  1. Data are presented as n (%), mean ± SD, median [IQR]. ACE angiotensin-converting enzyme inhibitor, AR angiotensin receptor, GLS global longitudinal strain, LVEDV left ventricular end-diastolic volume, LVEF left ventricular ejection fraction, LVESV left ventricular end-systolic volume, TAPSE tricuspid annular plane systolic excursion. * P value <0,05